Advanced Medical Isotope (OTCMKTS:RDGL – Get Free Report) and New Mountain Finance (NASDAQ:NMFC – Get Free Report) are both small-cap finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.
Risk and Volatility
Advanced Medical Isotope has a beta of -0.77, indicating that its stock price is 177% less volatile than the S&P 500. Comparatively, New Mountain Finance has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Profitability
This table compares Advanced Medical Isotope and New Mountain Finance’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Advanced Medical Isotope | -4,380.77% | N/A | -138.20% |
| New Mountain Finance | -18.65% | 11.14% | 4.63% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Advanced Medical Isotope | $70,000.00 | 485.88 | -$3.07 million | ($0.01) | -6.89 |
| New Mountain Finance | $327.08 million | 2.31 | $16.49 million | ($0.58) | -13.79 |
New Mountain Finance has higher revenue and earnings than Advanced Medical Isotope. New Mountain Finance is trading at a lower price-to-earnings ratio than Advanced Medical Isotope, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Advanced Medical Isotope and New Mountain Finance, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Advanced Medical Isotope | 0 | 0 | 0 | 0 | 0.00 |
| New Mountain Finance | 2 | 5 | 0 | 0 | 1.71 |
New Mountain Finance has a consensus price target of $9.25, indicating a potential upside of 15.63%. Given New Mountain Finance’s stronger consensus rating and higher probable upside, analysts clearly believe New Mountain Finance is more favorable than Advanced Medical Isotope.
Insider & Institutional Ownership
32.1% of New Mountain Finance shares are held by institutional investors. 18.5% of Advanced Medical Isotope shares are held by company insiders. Comparatively, 14.9% of New Mountain Finance shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
New Mountain Finance beats Advanced Medical Isotope on 9 of the 13 factors compared between the two stocks.
About Advanced Medical Isotope
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
About New Mountain Finance
New Mountain Finance Corporation (Nasdaq: NMFC), a business development company is a private equity / buyouts and loan fund specializes in directly investing and lending to middle market companies in defensive growth industries. The fund prefers investing in buyout and middle market companies. It also makes investments in debt securities at all levels of the capital structure including first and second lien debt, unsecured notes, and mezzanine securities. In some cases, its investments may also include equity interests. It targets energy, engineering and consulting services, specialty chemicals and materials, trading companies and distributors, commercial printing, diversified support services, education services, environmental and facilities services, office services and supplies, media, distributors, health care services, health care facilities, application software, business services, systems software, federal services, distribution and logistics, interactive home entertainment, telecommunication services, hydroelectric power generation, electric power generation by fossil fuels, electric power generation by nuclear fuels, health care technology, and security and alarm services. The fund seeks to invest in United States of America. It seeks to invest between $10 million and $125 million per transaction. The firm invests through both primary originations and open-market secondary purchases. It invests in companies with EBITDA between $10 million and $200 million. The fund seeks a majority stake in its portfolio companies.
Receive News & Ratings for Advanced Medical Isotope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Medical Isotope and related companies with MarketBeat.com's FREE daily email newsletter.
